Company registration number SC412459 (Scotland)
GREAT GLEN PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
GREAT GLEN PHARMA LTD
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 4
GREAT GLEN PHARMA LTD
BALANCE SHEET
AS AT
31 MARCH 2026
31 March 2026
- 1 -
2026
2025
Notes
£
£
£
£
Current assets
Debtors
3
1,339,001
1,339,001
Net current assets
1,339,001
1,339,001
Capital and reserves
Called up share capital
4
1,001
1,001
Share premium account
1,338,000
1,338,000
Total equity
1,339,001
1,339,001

For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 27 October 2026 and are signed on its behalf by:
Mr M Green
Director
Company registration number SC412459 (Scotland)
GREAT GLEN PHARMA LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026
- 2 -
Share capital
Share premium account
Total
£
£
£
Balance at 1 April 2024
1,001
1,338,000
1,339,001
Year ended 31 March 2025:
Profit and total comprehensive income
-
-
-
0
Balance at 31 March 2025
1,001
1,338,000
1,339,001
Year ended 31 March 2026:
Profit and total comprehensive income
-
-
-
0
Balance at 31 March 2026
1,001
1,338,000
1,339,001
GREAT GLEN PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 3 -
1
Accounting policies
Company information

Great Glen Pharma Ltd is a private company limited by shares incorporated in Scotland. The registered office is Bankell House, Strathblane Road, Milngavie, Glasgow, United Kingdom, G62 8LE.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Profit and loss account

The company has not traded during the year or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
0
0
3
Debtors
2026
2025
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
1,339,001
1,339,001
4
Called up share capital
2026
2025
2026
2025
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of 10p each
7
7
1
1
Ordinary B shares of £1 each
1,000
1,000
1,000
1,000
Ordinary C shares of 10p each
3
3
-
0
-
0
1,010
1,010
1,001
1,001
GREAT GLEN PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
4
Called up share capital
(Continued)
- 4 -

A & B Ordinary

 

Shares rank equally for voting purposes, on a show of hands each member shall have one vote and on a poll each member shall have one vote per share held.

 

Each share ranks equally for any dividend declared.

 

Each share ranks equally for any distribution made of a winding up.

 

C Ordinary

 

Shares have no voting, dividend or capital rights.

5
Debt Security

There is a floating charge, negative pledge and standard securities held by HSBC UK Bank plc over the company's assets securing all the company's liabilities due, or becoming due, to HSBC UK Bank plc.

6
Ultimate controlling party

Ultimate controlling ownership of the company is held by Mr & Mrs Green by virtue of their 100% shareholding in The M & D Green Group Limited (the company's parent company), the registered office of which is Bankell House, Strathblane Road, Milngavie, Glasgow, Scotland, G62 8LE.

The financial statements of the company are consolidated in the financial statements of The M&D Green Group Limited, this is the smallest and largest group in which the company is included. These consolidated financial statements are available from its registered office, Bankell House Strathblane Road, Milngavie, Glasgow, G62 8LE.

2026-03-312025-04-01falsefalsetrueCCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr M GreenMrs D A GreenSC4124592025-04-012026-03-31SC4124592026-03-31SC4124592025-03-31SC412459core:ShareCapital2026-03-31SC412459core:ShareCapital2025-03-31SC412459core:SharePremium2026-03-31SC412459core:SharePremium2025-03-31SC412459core:ShareCapital2024-03-31SC412459core:SharePremium2024-03-31SC412459core:ShareCapitalOrdinaryShareClass12026-03-31SC412459core:ShareCapitalOrdinaryShareClass12025-03-31SC412459core:ShareCapitalOrdinaryShareClass22026-03-31SC412459core:ShareCapitalOrdinaryShareClass22025-03-31SC412459core:ShareCapitalOrdinaryShareClass32026-03-31SC412459core:ShareCapitalOrdinaryShareClass32025-03-31SC412459core:ShareCapitalOrdinaryShares2026-03-31SC412459core:ShareCapitalOrdinaryShares2025-03-31SC412459bus:Director12025-04-012026-03-31SC4124592024-04-012025-03-31SC412459core:CurrentFinancialInstruments2026-03-31SC412459core:CurrentFinancialInstruments2025-03-31SC412459bus:OrdinaryShareClass12025-04-012026-03-31SC412459bus:OrdinaryShareClass22025-04-012026-03-31SC412459bus:OrdinaryShareClass32025-04-012026-03-31SC412459bus:OrdinaryShareClass12026-03-31SC412459bus:OrdinaryShareClass12025-03-31SC412459bus:OrdinaryShareClass22026-03-31SC412459bus:OrdinaryShareClass22025-03-31SC412459bus:OrdinaryShareClass32026-03-31SC412459bus:OrdinaryShareClass32025-03-31SC412459bus:AllOrdinaryShares2026-03-31SC412459bus:AllOrdinaryShares2025-03-31SC412459bus:EntityNoLongerTradingButTradedInPast2025-04-012026-03-31SC412459bus:PrivateLimitedCompanyLtd2025-04-012026-03-31SC412459bus:FRS1022025-04-012026-03-31SC412459bus:AuditExempt-NoAccountantsReport2025-04-012026-03-31SC412459bus:Director22025-04-012026-03-31SC412459bus:SmallCompaniesRegimeForAccounts2025-04-012026-03-31SC412459bus:FullAccounts2025-04-012026-03-31xbrli:purexbrli:sharesiso4217:GBP